NRx Pharmaceuticals (NRXP) is downgraded from ‘Buy’ to ‘Sell’ following failures in ZYESAMI and NRX-101 clinical trials.
NRx Pharmaceuticals: ‘Sell’ On ZYESAMI/NRX-101 Failures & Depression Market Uncertainty
Source: Seeking Alpha
Read Full Story →
